अApnaFunda
Menu

KOPRAN LTD (KOPRAN)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Divergence: price ahead of business (3 months)
Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.40 / 100
Profitability 29Growth 31Balance sheet 58
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.55 / 100
Price 98Earnings 27FII/DII 41

Passes these screensHigh MomentumPrice ahead of business

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹259.76 latest close · +34.4% over the last 90 sessions

₹200₹250₹300Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹200₹250₹300Jul 3Sep 4Nov 9

₹259.76 month-end · +93.1% over 12 months

₹100₹200Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹100₹200Nov '25May '26Nov '26

₹259.76 month-end · +0.7% over 3 years

₹100₹200₹300Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹100₹200₹300Nov '23May '25Nov '26

₹259.76 month-end · +496.5% since Jan '19

₹0₹100₹200₹300Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹0₹100₹200₹300Jan '19Dec '22Nov '26

52-week range ₹107.00 to ₹295.83 · 1-year volatility 52.2%

Was the rally earned?

+93%share price, 1 yearMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 18.6x to 50.1x); per-share earnings took off 47 points.
  • The share count barely moved.
Net profit growth: −47 pts. Points of the price return explained by net profit growing (or shrinking).−47 ptsNet profit growthP/E change: +141 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+141 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +93%+93%Share priceNet profit growth: −47 pts. Points of the price return explained by net profit growing (or shrinking).−47ProfitP/E change: +141 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+141P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +93%+93%Share price
Net profit growth-47 ptsNet profit fell about 28%, which lowers the price.
P/E change+141 ptsThe P/E rose from 18.6x to 50.1x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+1%share price, 3 yearsRoughly flat
  • The share price was roughly flat over 3 years (+1%).
  • The share count barely moved.
Net profit growth: −8 pts. Points of the price return explained by net profit growing (or shrinking).−8 ptsNet profit growthP/E change: +9 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+9 ptsP/E changeShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1 ptsShare count changeShare price: +1%+1%Share priceNet profit growth: −8 pts. Points of the price return explained by net profit growing (or shrinking).−8ProfitP/E change: +9 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+9P/EShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1SharesShare price: +1%+1%Share price
Net profit growth-8 ptsNet profit fell about 7%, which lowers the price.
P/E change+9 ptsThe P/E rose from 45.7x to 50.1x, which lifts the price.
Share count change-1 ptsShare count was little changed. More shares would count against the price.
+4%share price, 5 yearsRoughly flat
  • The share price was roughly flat over 5 years (+4%).
  • The share count rose 11%.
Net profit growth: −92 pts. Points of the price return explained by net profit growing (or shrinking).−92 ptsNet profit growthP/E change: +107 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+107 ptsP/E changeShare count change: −11 pts. Points of the price return explained by the share count changing. More shares count against the price.−11 ptsShare count changeShare price: +4%+4%Share priceNet profit growth: −92 pts. Points of the price return explained by net profit growing (or shrinking).−92ProfitP/E change: +107 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+107P/EShare count change: −11 pts. Points of the price return explained by the share count changing. More shares count against the price.−11SharesShare price: +4%+4%Share price
Net profit growth-92 ptsNet profit fell about 60%, which lowers the price.
P/E change+107 ptsThe P/E rose from 17.6x to 50.1x, which lifts the price.
Share count change-11 ptsShare count rose 11%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-72.1%not yet recovered
1-year volatility52.2%annualised
Beta vs sector index1.413-year daily, correlation 0.42
Volume spikes13last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%−60%2020202120222023202420252026−71.3% 0%−20%−40%−60%2020202220242026−71.3%
Largest drawdowns

-72.1% (2021-12 peak to 2023-03 low, not yet recovered)

-62.9% (2019-01 peak to 2020-03 low, recovered 2020-07)

-29.4% (2020-12 peak to 2021-03 low, recovered 2021-04)

Most recent volume spikes

2026-11-03: 5.1x the 50-day median, price +1.6% that day

2026-09-29: 5.9x the 50-day median, price +4.7% that day

2026-09-28: 5.9x the 50-day median, price -2.3% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

50.1xP/E todayNear its historic high
Against its own history98th percentile
CheapestMedian 19.3xDearest

Usual range 6.2x to 43.2x since 2019-01.

Against Health Technology50.1x vs 37.0x
This company
50.1x
Sector median
37.0x

36% above the Health Technology median.

4.6x23.1x41.6x60.1xJan '19Aug '20Mar '22Oct '23May '25Nov '264.6x23.1x41.6x60.1xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE27th▼ 6 pts vs a year ago
  • Op. margin31stflat vs a year ago
  • Revenue growth51st▲ 31 pts vs a year ago
  • EPS growth21st▲ 4 pts vs a year ago
  • Debt/equity ↓44th▲ 5 pts vs a year ago
  • Cash cycle ↓53rd▲ 13 pts vs a year ago
  • P/E ↓33rd▼ 50 pts vs a year ago
  • 12M momentum92nd▲ 70 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~18%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 30.7x, a holder earning 12%/yr needs earnings to grow about 18.1%/yr for 10 years, then trade at 15x.

Delivered7.2%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+11.0 ptsimplied minus delivered
Rank305thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%14%29% Jan 2019Nov 2026 0%14%29% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x19.4%20.5%21.6%
15x17.1%18.1%19.2%
20x14.1%15.1%16.1%

Drag a slider to test other assumptions

Implied: 18.1%/yr

Looking back

  • Jan 2020Price implied 16%/yr; EPS has since grown −0%/yr (7.0 yrs)
  • Jan 2021Price implied 18%/yr; EPS has since grown 2%/yr (6.0 yrs)
  • Jan 2022Price implied 24%/yr; EPS has since grown −18%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹259.76
P/E
50.1x
ROCE
7.0%
Market Cap
₹1255 cr
Revenue (TTM)
₹700 cr
P/S
1.8x
P/B
2.4x
ROE
4.7%
Operating Margin
10.3%
Debt / Equity
0.3x
Promoter Holding
44.4%
12M Momentum
93.1%

52-week range

₹107.00₹295.83
81% of the way from its 52-week low to its high

Price risk

1Y volatility
52.2%
Beta vs sector
1-year daily
1.43

Balance sheet & cash

Interest cover
operating profit ÷ interest
4.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.31x
Share count, 1Y
unchanged

Are profits backed by cash?

5 of 7checks within range1 beyond a threshold
Other income reliance7%Within range

Other income as a share of pre-tax profit (trailing twelve months): 6.7%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate25%Within range

Median quarterly effective tax rate over about 2.5 years: 24.7%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.31xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.31x (cash from operations ₹152 cr, net profit ₹116 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow0 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 0. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+16 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 16 days (141 vs 125). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress7% of fixed assetsWithin range

Capital work-in-progress is 7% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+28 days / 2 yrsWithin range

Days payable changed by +28 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, institutional and promoter holdings were broadly unchanged.
  • The number of shareholders rose from 51,636 to 56,925 (+10%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters44.5%44.4%-0.1 pts
FIIs0.5%0.5%0.0 pts
DIIs0.1%0.0%-0.1 pts
Public and others54.9%55.1%+0.2 pts

Number of shareholders

56,925shareholders+10% since Dec '23
51k55k58k62k Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 51,636
Mar '24: 50,850
Jun '24: 51,492
Sep '24: 57,154
Dec '24: 60,560
Mar '25: 58,652
Jun '25: 60,194
Sep '25: 62,222
Dec '25: 60,886
Mar '26: 58,639
Jun '26: 56,925
 51k55k58k62k Dec '23Dec '24Dec '25Jun '26
Dec '23: 51,636
Mar '24: 50,850
Jun '24: 51,492
Sep '24: 57,154
Dec '24: 60,560
Mar '25: 58,652
Jun '25: 60,194
Sep '25: 62,222
Dec '25: 60,886
Mar '26: 58,639
Jun '26: 56,925

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+4.4%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like KOPRAN LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −21% to +76% vs the market, against 0% for all non-financial companies in the same months.
  • The gap against the base rate (+4.0%, 80% range −7.6% to +18.2%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
MIRZAINT · Mar 2022: −61.0% vs market
LOKESHMACH · Mar 2024: −57.5% vs market
ADSL · Apr 2022: −43.8% vs market
MAHEPC · Aug 2025: −42.2% vs market
IFGLEXPOR · Apr 2021: −37.2% vs market
PRECAM · Aug 2023: −36.1% vs market
BBL · May 2024: −34.3% vs market
KILITCH · Jan 2024: −33.3% vs market
STERTOOLS · Feb 2023: −29.6% vs market
AJMERA · Aug 2021: −29.1% vs market
SCHAND · Apr 2023: −27.1% vs market
ALKALI · Apr 2020: −25.0% vs market
SUDARSCHEM · Mar 2025: −22.4% vs market
ORIENTBELL · May 2022: −16.3% vs market
TTKHLTCARE · Apr 2023: −15.4% vs market
SKMEGGPROD · May 2023: −14.0% vs market
KOKUYOCMLN · Jun 2023: −13.4% vs market
CLEDUCATE · Jun 2022: −12.8% vs market
LUMAXIND · Mar 2023: −8.3% vs market
AXISCADES · May 2023: −7.4% vs market
SANGHIIND · Mar 2023: −6.7% vs market
AVTNPL · Apr 2020: −6.3% vs market
TVSSRICHAK · Jan 2023: −3.8% vs market
SALASAR · Dec 2022: 0% vs market
ASTRAMICRO · Aug 2022: +2.3% vs market
HPL · Apr 2024: +6.4% vs market
JBMA · Dec 2021: +10.6% vs market
HBLENGINE · Dec 2020: +13.5% vs market
MMFL · Jul 2021: +18.7% vs market
GRPLTD · May 2024: +20.9% vs market
SOMANYCERA · Feb 2021: +40.6% vs market
ARTEMISMED · May 2023: +42.0% vs market
TIRUMALCHM · Nov 2020: +55.9% vs market
RISHABH · Aug 2025: +57.5% vs market
PRICOLLTD · Oct 2022: +66.1% vs market
AVALON · May 2025: +73.0% vs market
KIRLOSENG · Apr 2023: +75.7% vs market
ICIL · Feb 2020: +75.8% vs market
KOTARISUG · Jun 2020: +76.5% vs market
WINDMACHIN · Sep 2023: +77.9% vs market
IGPL · Oct 2020: +79.6% vs market
KIRLOSBROS · May 2023: +109.2% vs market
TEXRAIL · Nov 2022: +109.7% vs market
PREMEXPLN · Aug 2022: +112.7% vs market
APOLLO · May 2023: +118.7% vs market
MARINE · Nov 2023: +121.9% vs market
NEULANDLAB · Mar 2023: +135.9% vs market
SANGHVIMOV · Mar 2023: +158.4% vs market
SOUTHWEST · Mar 2021: +199.4% vs market
SHAILY · Mar 2024: +232.8% vs market
Similar setups +4.4%All companies +0.4%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 9 beyond the range shown, drawn at the edge

Similar setups' median
+4.4%
All companies' median
+0.4%
Beat the market
54% vs 50%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
APOLLO
Electronic Technology		 May 2023 48x9% +155%−7% +119%
LOKESHMACH
Technology Services		 Mar 2024 69x10% +237%−6% −58%
STERTOOLS
Producer Manufacturing		 Feb 2023 47x9% +137%−10% −30%
GRPLTD
Producer Manufacturing		 May 2024 85x9% +147%−5% +21%
BBL
Producer Manufacturing		 May 2024 59x9% +184%−8% −34%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
HBLENGINE
Producer Manufacturing		 Dec 2020 43x6% +159%−3% +14%
PRECAM
Producer Manufacturing		 Aug 2023 53x8% +111%−2% −36%
MARINE
Producer Manufacturing		 Nov 2023 68x14% +166%−4% +122%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/S and P/E. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to KOPRAN LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

SOM DISTILLERIES N BREWERIES LSDBL
Consumer Non-Durables
76%similar
volatilitydebt/equity
GANESHA ECOSPHEREGANECOS
Process Industries
73%similar
ROCErevenue growth
XPRO INDIAXPROINDIA
Process Industries
72%similar
volatilityoperating margin
ASIAN GRANITO INDIAASIANTILES
Producer Manufacturing
70%similar
debt/equityvolatility
BHAGIRADHA CHEMICALS AND INDUSBHAGCHEM
Process Industries
66%similar
revenuedebt/equity
SIGACHI INDUSTRIESSIGACHI
Health Technology
73%similar
debt/equityROCE
ZIM LABORATORIESZIMLAB
Health Technology
57%similar
ROCEvolatility
BAJAJ HEALTHCAREBAJAJHCARE
Health Technology
50%similar
revenueP/E

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jun '23

  1. NovPriceVolume reached 5.1x its 50-day median on 2026-11-03; price +1.6% that day.
  2. SepValuationP/E crossed above the 90th percentile of its own history to date (53.7x).
  3. SepPriceVolume reached 115.8x its 50-day median on 2026-09-15; price +6.2% that day.
  4. JunResultsRevenue (TTM) reached a new high of ₹681 cr.
  5. JunPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  6. MayPriceVolume reached 49.8x its 50-day median on 2026-05-25; price +15.5% that day.
  7. AprValuationP/E crossed above the 90th percentile of its own history to date (48.0x).
  8. JanPriceVolume reached 5.4x its 50-day median on 2026-01-22; price +0.8% that day.
Show 22 earlier events
  1. DecValuationP/E crossed above the 90th percentile of its own history to date (41.2x).
  2. DecPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
  3. DecPriceVolume reached 91.7x its 50-day median on 2025-12-23; price +14.5% that day.
  4. SepPriceVolume reached 10.3x its 50-day median on 2025-09-03; price +8.2% that day.
  5. JunResultsYear-on-year EPS growth turned negative.
  6. JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
  7. JunPriceVolume reached 8.6x its 50-day median on 2025-06-03; price +2.4% that day.
  8. MarResultsRevenue (TTM) reached a new high of ₹643 cr.
  9. MarPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  10. MarPriceVolume reached 6.0x its 50-day median on 2025-03-21; price +8.1% that day.
  11. DecPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
  12. AugPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
  13. AugPriceVolume reached 18.2x its 50-day median on 2024-08-19; price +11.2% that day.
  14. JunResultsYear-on-year EPS growth turned positive.
  15. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
  16. JunPriceVolume reached 10.1x its 50-day median on 2024-06-13; price +8.8% that day.
  17. FebPriceVolume reached 11.9x its 50-day median on 2024-02-07; price +7.0% that day.
  18. NovPriceVolume reached 16.5x its 50-day median on 2023-11-20; price +9.9% that day.
  19. AugPriceVolume reached 21.5x its 50-day median on 2023-08-24; price +18.9% that day.
  20. JunResultsRevenue (TTM) reached a new high of ₹551 cr.
  21. JunValuationP/E crossed above the 90th percentile of its own history to date (33.0x).
  22. JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1150.1x₹700 cr4.7%7.0%0.3x
2026-1046.1x₹700 cr4.7%7.0%0.3x
2026-0953.7x₹700 cr4.7%7.0%0.3x
2026-0840.9x₹681 cr4.9%7.0%0.3x
2026-0735.8x₹681 cr4.9%7.0%0.3x
2026-0635.5x₹681 cr4.9%7.0%0.3x
2026-0560.1x₹620 cr3.2%10.0%0.3x
2026-0448.0x₹620 cr3.2%10.0%0.3x
2026-0331.5x₹620 cr3.2%10.0%0.3x
2026-0236.1x₹592 cr3.4%10.0%0.3x
2026-0135.1x₹592 cr3.4%10.0%0.3x
2025-1241.2x₹592 cr3.4%10.0%0.3x
2025-1118.6x₹625 cr6.7%10.0%0.3x
2025-1022.8x₹625 cr6.7%10.0%0.3x
2025-0924.1x₹625 cr6.7%10.0%0.3x
2025-0819.4x₹630 cr7.4%10.0%0.3x
2025-0720.1x₹630 cr7.4%10.0%0.3x
2025-0623.6x₹630 cr7.4%10.0%0.3x
2025-0518.6x₹643 cr9.7%14.0%0.2x
2025-0419.6x₹643 cr9.7%14.0%0.2x
2025-0317.8x₹643 cr9.7%14.0%0.2x
2025-0215.3x₹636 cr10.8%14.0%0.2x
2025-0116.6x₹636 cr10.8%14.0%0.2x
2024-1219.3x₹636 cr10.8%14.0%0.2x
2024-1117.7x₹637 cr12.1%14.0%0.2x
2024-1023.3x₹637 cr12.1%14.0%0.2x
2024-0926.9x₹637 cr12.1%14.0%0.2x
2024-0828.3x₹615 cr10.4%14.0%0.2x
2024-0725.1x₹615 cr10.4%14.0%0.2x
2024-0624.0x₹615 cr10.4%14.0%0.2x
2024-0539.9x₹551 cr6.2%8.0%0.2x
2024-0446.2x₹551 cr6.2%8.0%0.2x
2024-0345.8x₹551 cr6.2%8.0%0.2x
2024-0243.6x₹551 cr6.2%8.0%0.2x
2024-0147.3x₹551 cr6.2%8.0%0.2x
2023-1242.7x₹551 cr6.2%8.0%0.2x
2023-1145.7x₹551 cr6.2%8.0%0.2x
2023-1039.9x₹551 cr6.2%8.0%0.2x
2023-0940.1x₹551 cr6.2%8.0%0.2x
2023-0842.2x₹551 cr6.2%8.0%0.2x
2023-0735.2x₹551 cr6.2%8.0%0.2x
2023-0633.0x₹551 cr6.2%8.0%0.2x
2023-0512.2x₹478 cr14.3%21.0%0.2x
2023-0412.1x₹478 cr14.3%21.0%0.2x
2023-038.7x₹478 cr14.3%21.0%0.2x
2023-028.7x₹478 cr14.3%21.0%0.2x
2023-0110.2x₹478 cr14.3%21.0%0.2x
2022-1211.9x₹478 cr14.3%21.0%0.2x
2022-1112.7x₹478 cr14.3%21.0%0.2x
2022-1014.3x₹478 cr14.3%21.0%0.2x
2022-0912.5x₹478 cr14.3%21.0%0.2x
2022-0814.7x₹478 cr14.3%21.0%0.2x
2022-0715.9x₹478 cr14.3%21.0%0.2x
2022-0615.9x₹478 cr14.3%21.0%0.2x
2022-0516.0x₹492 cr25.3%30.0%0.3x
2022-0419.7x₹492 cr25.3%30.0%0.3x
2022-0319.7x₹492 cr25.3%30.0%0.3x
2022-0219.3x₹492 cr25.3%30.0%0.3x
2022-0120.1x₹492 cr25.3%30.0%0.3x
2021-1222.7x₹492 cr25.3%30.0%0.3x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback